Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands
Department of Pulmonology, St Antonius Hospital, Nieuwegein, the Netherlands
M.C. Post Department of Cardiology, St Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands
Background. Inoperable chronic thromboembolic pulmonary hypertension (CTEPH) is associated with a poor survival.
Objectives. To evaluate the long-term response to a dual endothelin receptor antagonist in patients with inoperable CTEPH.
Methods. All consecutive 18 patients (mean age 63±14 years) treated with bosentan for symptomatic inoperable CTEPH were included. Efficacy was evaluated by the log value of serum levels of N-terminal-pro brain natriuretic peptide (log NTpro BNP), New York Heart Association functional class (NYHA), and the six-minute walk test (6-MWT). All follow-up data (median 31 months) were compared with baseline and divided into: short-term (<12 months), mid-term (between 12 and 24 months), and long-term follow-up (>24 months).
Results. At baseline, 15 patients were in NYHA class III and three in NYHA class IV, mean log NT-pro BNP level was 7.2±1.4 log pg/ml, and mean 6-MWT distance was 404±125 m. During short-term follow-up (n=18), the NYHA class improved (p=0.001), 6-MWT distance increased by 33 m (p=0.03), and log NT-pro BNP decreased to 6.9±1.4 log pg/ml (p=0.007). During mid-term follow-up (n=17), the NYHA class improved (p<0.001), the mean 6-MWT distance increased by 41 m (p=0.01), and log NT-pro BNP was 6.9±1.4 log pg/ml (p=0.31). During late followup (n=14) the NYHA class was still improved (p=0.03), the 6-MWT distance decreased by 9 m (p=0.73), and log NT-pro BNP was 7.1±1.5 log pg/ml (p=0.91). The overall four year survival rate was 88%.
Conclusion: Bosentan seems to be effective during long-term treatment in patients with inoperable CTEPH. (Neth Heart J 2009;17:329–33).
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J. 1992; 5: 334–42.
Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006; 130: 172–5.
Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982; 81: 151–8.
Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003; 76: 1457–62.
Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Sys Rev 2006; 3: CD004434.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896–903.
Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006; 70: 1058–63.
Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128: 2599–603.
Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128: 2363–7.
Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28: 138–43.
Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005; 60: 707.
Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. Endpoints and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004; 43: 48S–55S.
Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102: 865–70.
Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration. 2007; 74: 287–92.
- Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension
M. C. Post
H. W. M. Plokker
J. C. Kelder
R. J. Snijder
- Bohn Stafleu van Loghum
Neu im Fachgebiet Kardiologie
e.Med Kampagnen-Visual, Mail Icon II